Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Keytruda
Keytruda
Merck tacks on armor in early-line cancer fight with 2 Keytruda wins setting the tone
Endpoints
Wed, 05/19/21 - 11:10 pm
Merck
Keytruda
ASCO 2021
FDA review of Lilly/Innovent’s sintilimab paves way for cut-price immunotherapy option
Pharmaforum
Wed, 05/19/21 - 10:26 am
Eli Lilly
Innovent
China
sintilimab
Keytruda
Merck
immunotherapy
Merck, with new breast cancer data, aims to rebound from FDA rejection
BioPharma Dive
Thu, 05/13/21 - 12:00 pm
Merck
Keytruda
breast cancer
clinical trials
FDA
triple negative breast cancer
Merck's Blockbuster Cancer Antibody Racks Up Another Approval
BioSpace
Thu, 05/6/21 - 10:59 pm
Merck
Keytruda
FDA
Herceptin
gastric adenocarcinoma
Pandemic slowed sales of cancer, arthritis, diabetes drugs
Beckers Hospital Review
Mon, 05/3/21 - 10:48 am
COVID-19
pandemic
cancer
diabetes
arthritis
Merck
Keytruda
Amgen
Enbrel
Keytruda should lose stomach cancer indication, says ODAC
Pharmaforum
Fri, 04/30/21 - 11:09 am
Merck
Keytruda
ODAC
gastric cancer
stomach cancer
Merck, Roche and Bristol Myers nab 4 of 6 positive ODAC votes for ‘dangling’ accelerated approvals
Endpoints
Thu, 04/29/21 - 10:55 pm
Merck
Roche
Bristol Myers Squibb
FDA
ODAC
accelerated approvals
Keytruda
Opdivo
Tecentriq
ODAC votes to keep Keytruda and Tecentriq accelerated approvals in bladder cancer
Endpoints
Wed, 04/28/21 - 10:12 pm
FDA
ODAC
accelerated approvals
Merck
Keytruda
Roche
Tecentriq
What are Merck, Bristol Myers and Roche planning for the big FDA cancer approval review?
Fierce Pharma
Tue, 04/27/21 - 11:04 am
FDA
oncology
accelerated approvals
Merck
Keytruda
Bristol Myers Squibb
Opdivo
Roche
Tecentriq
FDA Advisory Committee to Review Checkpoint Inhibitors Greenlit Under Accelerated Approval
BioSpace
Sun, 04/25/21 - 01:56 pm
FDA
oncology
cancer
accelerated approvals
Bristol Myers Squibb
Opdivo
Roche
Tecentriq
Merck
Keytruda
GSK stops Keytruda combo trials after ICOS drug falls short
Fierce Biotech
Thu, 04/15/21 - 10:37 am
GSK
feladilimab
Keytruda
clinical trials
ICOS
Merck's Keytruda, on the heels of a first-line kidney cancer win, targets earlier, post-surgery use
Fierce Pharma
Thu, 04/8/21 - 11:13 am
Merck
Keytruda
renal cell carcinoma
kidney cancer
clinical trials
FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
Endpoints
Mon, 03/29/21 - 11:09 pm
Merck
FDA
Keytruda
triple negative breast cancer
FDA busts Merck's Keytruda in triple-negative breast cancer with a CRL — not unexpected given its disastrous adcomm
Endpoints
Mon, 03/29/21 - 11:09 pm
Merck
FDA
Keytruda
triple negative breast cancer
Merck Scores Latest Label Expansion for Keytruda in Esophageal Carcinomas
BioSpace
Tue, 03/23/21 - 11:23 pm
Merck
Keytruda
esophageal cancer
FDA
Merck breathes a sigh of relief as Keytruda-Lenvima combo aces confirmatory study in endometrial cancer
Endpoints
Fri, 03/19/21 - 10:51 am
Merck
FDA
Keytruda
Eisai
Lenvima
clinical trials
endometrial cancer
Surface Oncology To Test SRF388 Plus Keytruda Combo In Solid Tumor Settings
Benzinga
Tue, 03/9/21 - 09:39 pm
Surface Oncology
Merck
Keytruda
SRF388
solid tumors
Merck follows Bristol's suit, pulling Keytruda's SCLC nod. Is the FDA's accelerated approval reckoning finally here?
Fierce Pharma
Tue, 03/2/21 - 12:14 pm
Merck
Keytruda
FDA
small cell lung cancer
Opdivo
Bristol-Myers Squibb
Libtayo scores second OK in two weeks, this time for front-line NSCLC. Can it take on Keytruda?
Endpoints
Mon, 02/22/21 - 11:51 pm
Regeneron
Libtayo
non-small cell lung cancer
Merck
Keytruda
Did Merck Make a Mistake With a Key FDA Filing?
Motley Fool
Sun, 02/21/21 - 11:54 pm
Merck
Keytruda
FDA
triple negative breast cancer
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »